Key Highlights

  • MBX Biosciences (NASDAQ: MBX) appoints Steven Hoerter as CEO with a $665,000 base salary and an equity package including stock options.
  • Both executives’ equity awards vest in 25% increments over a four-year period.
  • The company’s leadership transition includes structured compensation and advisory support.

MBX Biosciences (NASDAQ: MBX) has announced key leadership changes, appointing Steven Hoerter as CEO and John Smither as CFO. The moves reflect the company’s strategic direction as it continues to advance its pipeline in the biotechnology sector.

Leadership Transition Timeline

The board finalized the appointments on July 9, 2026, with both executives assuming their roles shortly thereafter. The transition period includes advisory support to maintain operational continuity during the shift.

New CEO Compensation

Hoerter’s compensation package includes a base salary of $665,000, with a target annual bonus set at 60% of that amount. As part of his long-term incentives, he will receive stock options to purchase 331,000 shares, along with a restricted stock unit award covering 71,000 shares. These awards will become exercisable in 25% increments over a four-year period, aligning his interests with the company’s performance.

CFO Appointment Details

Smither’s compensation includes a base salary of $530,000 and a target annual bonus of 40%. His equity package includes a stock unit award covering 28,000 shares, which will vest in 25% increments over four years, subject to continued employment.

Equity Awards Structure

The equity awards for both executives follow a structured vesting schedule, designed to incentivize long-term commitment. Hoerter’s and Smither’s restricted stock units will vest in equal annual portions, ensuring alignment with the company’s strategic goals. The terms of these awards are standard for executive compensation in the biotech industry, where retention and performance are critical.

Board and Governance Notes

The appointments were made following a thorough review by the board, ensuring compliance with governance standards. Both executives’ employment agreements are at-will, with full details to be disclosed in the company’s upcoming regulatory filings. The board confirmed that no conflicts of interest exist in these appointments.

Strategic Advisory Role

As part of the transition, the company has arranged for advisory support to facilitate knowledge transfer and maintain stability. This arrangement will continue through mid-August 2026, providing the new leadership team with insights into ongoing projects and strategic initiatives. The leadership changes come at a pivotal time for MBX Biosciences, as the company advances its clinical programs and seeks to strengthen its position in the competitive biotech environment.

The structured compensation packages reflect the board’s confidence in the new executives’ ability to drive growth and innovation.

This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.